Psychedelic Integration Therapy
An in-depth look at the pharmacodynamics, pharmacokinetics, pharmacogenomics, and neuroscience of psychedelics.
Faculty
Dates & Times
All sessions on EST until March 12, EDT from March 13 through end date.
Location
Cost
Course Description
This reading and study group will maintain the same membership for the 12-week period. The group will have a syllabus with readings that participants will be expected to read prior to each discussion group meeting. The format for each session will include a short review of each paper by the group leader, followed by a discussion of the content and group members’ perspectives of the topic. This is an active group and weekly participation is required. The group is ideal for clinicians, graduate students, researchers, or the public, so long as they have training or interest in the biological responses that may influence the efficacy and safety of psychedelic therapy. Readings will include publications in the academic literature. The articles will provide an overview of psychedelic effects investigated by a variety of scientific methods (pharmacodynamics, pharmacokinetics, pharmacogenomics, neuroscience) for several types of psychedelics (e.g., psilocybin, ayahuasca, MDMA, ketamine).
A limited number of Diversity Fund scholarships are available, please complete this application, in addition to the course application.
Learning Objectives
At the end of this course, the participant will be able to:
- Describe pharmacokinetic properties of psilocybin to predict potential drug interactions and adverse effects
- Describe pharmacokinetic properties of ayahuasca to predict potential drug interactions and adverse effects
- Describe pharmacokinetic properties of MDMA to predict potential drug interactions and adverse effects
- Describe pharmacokinetic properties of ketamine to predict potential drug interactions and adverse effects
- Explain how the pharmacodynamics of psilocybin affects clinical and serological biomarkers
- Explain how the pharmacodynamics of ayahuasca affects clinical and serological biomarkers
- Explain how the pharmacodynamics of MDMA affects clinical and serological biomarkers
- Explain how the pharmacodynamics of ketamine affects clinical and serological biomarkers
- Discuss the effects of psilocybin on neural network function
- Discuss the effects of ayahuasca on neural network function
- Discuss the effects of MDMA on neural network function
- Discuss the effects of ketamine on neural network function
Perks
- Registration includes access to our online classroom, course handouts, and private course discussion board. All attendees may opt to be added to our professional community email list of over 800 professionals who have completed this (or similar) courses with us.
Other Upcoming Courses
Integrating Psychedelics with Evidence-Based Therapy Reading and Study Group Fall 2022
Poetry, Symbols, and Story in Psychedelic Therapy | Fall 2022
Psychedelic Integration: Experiential Training Retreat for Clinicians | Stony Point, NY 2022
Understanding Ketamine Summer 2022 | Online
Integrating Psychedelics with Evidence-Based Therapy Reading and Study Group Fall 2022
Poetry, Symbols, and Story in Psychedelic Therapy | Fall 2022
Psychedelic Integration: Experiential Training Retreat for Clinicians | Stony Point, NY 2022
Understanding Ketamine Summer 2022 | Online
Integrating Psychedelics with Evidence-Based Therapy Reading and Study Group Fall 2022
Poetry, Symbols, and Story in Psychedelic Therapy | Fall 2022